Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (917)	10/14/1998 12:17:00 PM
From: Anthony Wong	Respond to of 1722

Pfizer Inc. (PFE) rose as much as 4 1/4 to 91 3/4 as the drugmaker was reiterated ''buy'' by analyst Premal Pajwani at Dresdner Kleinwort Benson Securities Ltd. The maker of the impotence drug Viagra had pharmaceutical sales growth of 26 percent in the third quarter, Pajwani said, and the company has a broad range of products currently on the market and in the pipeline. Investor focus will shift away from Viagra in the fourth quarter, Pajwani added, to focus on Celebra, the arthritis drug Pfizer is marketing with Monsanto Co. (MTC), scheduled to go on the market in the first quarter of 1999. The drug has a head- start on Merck & Co.'s (MRK) arthritis drug, Vioxx, he said. Pfizer's third-quarter profit from operations rose to 51 cents a share from 45 cents a year earlier. From US Equity Movers, Bloomberg News October 14, 1998 11:33a.m. ET